ArticleBJUI compass2025
Time to abandon routine urine analysis prior to Bacillus Calmette-Guérin administration in asymptomatic patients.
Article in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to determine whether asymptomatic bacteriuria (ABU) increases the risk of infective complications requiring hospitalisation in patients undergoing Bacillus Calmette-Guérin (BCG) instillations and consequently evaluate the need to screen asymptomatic patients for bacteriuria prior to BCG administration. Subjects/patients and methods: We analysed retrospectively all patients who received ≥1 BCG instillations as treatment of NMIBC in Helsinki University Hospital and Turku University Hospital during 2009-2018. Patients submitted urine specimens 1-7 days prior to every BCG instillation. Urine culture results and possible antibiotic prophylaxis prior to BCG administration were recorded. ABU was classified as having a positive urine culture but no dysuria or fever. All hospital admissions because of urinary tract infections and other BCG-related adverse effects within 2 weeks of BCG administration were recorded. Results: We analysed 802 patients and 12 968 BCG instillations. ABU was recorded prior to 2428 (19%) instillations among which antibiotics were used in 527 (22%). Hospital admission was recorded after 9 (0,3%) and 39 (0,4%) instillations in the ABU and in the sterile urine groups, respectively ( Conclusion: BCG instillation with ABU is safe, and the results do not support routine screening of asymptomatic patients for bacteriuria prior to intravesical BCG immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.